Daré Bioscience, Inc. — Q1 2018 Form 10-Q
Reporting period: Three months ended March 31, 2018. Daré is a clinical-stage biopharmaceutical company focused on women’s reproductive health. It reported no revenue and has not generated revenue from its core business to date.
Financial and operating performance
| Metric | Q1 2018 | Q1 2017 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $7.68 million | $228,463 |
| Net loss | $7.67 million | $243,863 |
| Net loss per share, basic and diluted | $0.88 | $0.27 |
| Net cash used in operating activities | $2.12 million | $50,595 |
Gross and operating margins are not meaningful because the company had no revenue. The period-over-period comparison is limited: Q1 2018 reflects operations after the July 2017 Cerulean/Private Daré stock purchase transaction, while Q1 2017 reflects the operations of private Daré.
- Expenses and unusual item: R&D expense was $1.09 million, up from $27,800, primarily due to Ovaprene development. G&A was $1.30 million, up from $200,663, largely reflecting public-company professional costs, personnel, and insurance. A $5.19 million goodwill impairment was recorded in Q1 2018; this noncash charge accounted for most of the reported loss increase.
- Cash and liquidity: Cash and cash equivalents were $15.63 million at March 31, 2018, versus $7.56 million at year-end 2017. Working capital was approximately $15.1 million. Total current liabilities were $807,607; the filing reports no outstanding debt at quarter-end.
- Financing and capitalization: Q1 financing activities provided $10.20 million net. The company raised approximately $835,000 net through its at-the-market program and approximately $9.4 million net from a February offering of 5.0 million common shares and warrants for up to 3.5 million shares. Total common shares outstanding were 11,422,161 at March 31, 2018. Warrants include price-based anti-dilution provisions and may contribute to future dilution.
Changes, outlook, and risks
Management said existing cash was expected to fund operations for at least 12 months, and to support an Ovaprene postcoital clinical trial during 2018 and advancement of SST-6007 into a Phase 2b trial. These are management expectations, not a guarantee; the company cautioned that its estimates depend on assumptions and that additional capital will be required over time. It expects losses to continue for at least several years.
- At the time of the filing, management expected to begin the Ovaprene postcoital study in the first half of 2018 and, subject to FDA authorization, an SST-6007 Phase 2b trial in the second half of 2018.
- The portfolio included clinical-stage Ovaprene, a non-hormonal monthly contraceptive candidate, and SST-6007 topical sildenafil for female sexual arousal disorder. A March agreement with Orbis covers early development of injectable contraceptive candidates, with a $300,000 Stage One commitment and a later option for additional development funding.
- Subsequent to quarter-end, Daré licensed Juniper’s intravaginal-ring portfolio, with potential milestone payments of up to $43.75 million per covered product or process, plus royalties. It also signed a merger agreement with Pear Tree; closing was not certain, and the proposed acquisition would add a vaginal tamoxifen candidate and contingent royalty and milestone obligations.
- Daré announced an NIH award of $224,665 as the first portion of anticipated $1.9 million funding for Ovaprene; the remaining amount is contingent, among other things, on research results and funding availability.
- Key risks include continued dependence on additional financing, clinical and regulatory uncertainty, limited resources to advance the expanding portfolio, reliance on licensors and third-party manufacturers, and potential license termination if contractual obligations are not met. Product candidates have not been approved, and commercialization is uncertain.
Important facts for investors to verify
- Whether cash burn and clinical-development costs remain consistent with management’s stated 12-month liquidity outlook.
- Progress, timing, safety, and efficacy results for the Ovaprene and SST-6007 clinical programs, including required regulatory authorizations.
- Potential dilution from future capital raises and the 3.72 million warrants outstanding from the February offering, including their anti-dilution terms.
- Status and financial terms of the Pear Tree merger, Juniper license, and contingent NIH grant funding.
- Goodwill impairment assumptions and the scale of future milestone, royalty, and development commitments under product agreements.